Takeda’s Bid For Millennium May Face Several Hurdles – Pharma Analyst
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Several factors could still prevent Japan's top drug company Takeda from acquiring U.S.-based Millennium Pharmaceuticals, a pharmaceutical analyst said in an interview with PharmAsia News
You may also be interested in...
Astellas Pharma Branches Out In U.S., Offers Career-building Workshops To Employees
With the national unemployment rate hitting 8.5 percent in March, the highest in 25 years, many U.S. pharmaceutical companies - once considered to have relatively strong cash reserves and traditionally immune to economic recessions - have begun slashing payrolls and announcing tens of thousands of layoffs
Astellas Pharma Branches Out In U.S., Offers Career-building Workshops To Employees
With the national unemployment rate hitting 8.5 percent in March, the highest in 25 years, many U.S. pharmaceutical companies - once considered to have relatively strong cash reserves and traditionally immune to economic recessions - have begun slashing payrolls and announcing tens of thousands of layoffs
Following Millennium Merger, Takeda's Hopes Dashed To Be Among Number Three In Japan
Takeda and Millennium's combined oncology unit has 13 molecules in clinical development, six of which are in Phase II or III, including potential first-in-class opportunities